Gayathri Kallukaran is a Junior Journalist with Eastern Eye. She has a Master’s degree in Journalism and Mass Communication from St. Paul’s College, Bengaluru, and brings over five years of experience in content creation, including two years in digital journalism. She covers stories across culture, lifestyle, travel, health, and technology, with a creative yet fact-driven approach to reporting. Known for her sensitivity towards human interest narratives, Gayathri’s storytelling often aims to inform, inspire, and empower. Her journey began as a layout designer and reporter for her college’s daily newsletter, where she also contributed short films and editorial features. Since then, she has worked with platforms like FWD Media, Pepper Content, and Petrons.com, where several of her interviews and features have gained spotlight recognition. Fluent in English, Malayalam, Tamil, and Hindi, she writes in English and Malayalam, continuing to explore inclusive, people-focused storytelling in the digital space.
A new highly transmissible Covid variant, known as ‘Nimbus’, is raising concerns among health experts as cases rise sharply in parts of Asia and begin to appear in the UK. Official data shows that the strain, which has been labelled N.B.1.8.1, could drive a summer wave of infections due to its increased contagiousness and potential to evade immunity from earlier vaccinations or infections.
Cases detected in the UK
According to the UK Health Security Agency (UKHSA), 13 confirmed cases of the variant have already been recorded in England, and 25 British samples have been submitted to international databases since the end of March. However, experts say these figures likely underestimate the true spread, given the current limited Covid testing regime compared to the height of the pandemic.
UKHSA data up to 1 June reveals that 6.1 per cent of those tested for Covid were positive—the highest weekly figure for 2025. This marks a 7 per cent increase from the previous week and a 97 per cent rise compared to early March.
Rapid international spread
Nimbus, which is a descendant of the Omicron family of variants, has been linked to a spike in cases in China, Singapore, and Hong Kong. Globally, it now accounts for around 10.7 per cent of Covid infections, up from just 2.5 per cent a month earlier, according to the World Health Organisation (WHO).
The WHO has designated the variant as a ‘variant under monitoring’, which means it is being tracked for its potential impact but is not currently classified as a variant of concern.
Scientists warn of summer spike
British scientists are now warning that the new strain could fuel a rise in cases over the summer months, particularly as people become more socially active during the warmer weather.
Professor Lawrence Young, a virologist at Warwick University, said: “We are very likely to see a spike of infections over the next couple of months, possibly by later this month or in July. But it’s difficult to predict the level of this infection wave.”
He explained that population immunity from previous vaccinations or infections is likely waning, and unlike flu, Covid continues to spread in hot and humid weather. Laboratory studies also suggest that Nimbus is more efficient at infecting human cells and may have enhanced abilities to evade the immune system.
No evidence of increased severity
Despite its contagiousness, there is currently no indication that Nimbus causes more severe illness or higher mortality rates than earlier strains. However, experts caution that vulnerable groups—such as the elderly, people in care homes, and those with weakened immune systems—remain at risk of serious illness.
Data from the Office for National Statistics indicates that Covid contributed to just over 300 deaths in England during May 2025.
Symptoms and vaccine protection
The symptoms of the Nimbus variant appear to be consistent with those of previous Covid strains. These include fatigue, fever, sore throat and muscle aches.
There is currently no suggestion that the variant causes different or more severe symptoms. Moreover, scientists believe that existing Covid vaccines, reformulated to tackle Omicron and its descendants, should still offer protection against Nimbus.
UKHSA data shows that people who received a Covid booster last spring were 45 per cent less likely to require hospital treatment compared to those who remained unvaccinated.
Who is eligible for the vaccine?
In the UK, free Covid vaccinations are currently being offered to:
Adults over the age of 75
Residents and staff in care homes
Individuals with weakened immune systems
The UKHSA has urged all eligible people to take up the vaccine offer to help protect themselves and others from severe illness, particularly with the rising presence of the Nimbus strain.
Officials closely monitoring situation
Dr Gayatri Amirthalingam, deputy director at UKHSA, confirmed that the agency is closely tracking the spread of the N.B.1.8.1 variant both domestically and internationally.
“UKHSA is monitoring all available data relating to SARS-CoV-2 variants in the UK and abroad, and we continue to publish our findings in our regular Flu and Covid-19 surveillance reports,” she said.
“NB.1.8.1 has been detected in small numbers in the UK to date, but international data suggests that it is growing as a proportion of all Covid-19 cases.”
As the summer approaches, experts are reminding the public that even though the pandemic is no longer dominating daily life, Covid continues to evolve. The emergence of Nimbus underscores the need for vigilance, particularly among those at higher risk.
NHS encourages unvaccinated people aged 16–25 to get the HPV vaccine
Over 418,000 school leavers in past three years missed vaccination
HPV vaccine protects against cervical and other related cancers
NHS aiming for 90% uptake among girls by 2040
Letters, emails, texts and NHS App alerts being used for reminders
NHS campaign targets unvaccinated young adults
The NHS is urging hundreds of thousands of young people aged 16 to 25 to come forward for the HPV vaccine, which protects against cervical and other types of cancer.
Many of those targeted missed their vaccine during school years. According to NHS England, over 418,000 children left school without receiving the HPV jab in the past three years.
As part of a national campaign to increase uptake, GP practices are contacting eligible patients using letters, text messages, emails and the NHS App.
Addressing regional disparities and missed vaccinations
The vaccine is routinely offered to boys and girls aged 12 to 13. However, government data from June 2024 highlighted regional inequalities in vaccine uptake. The lowest rates were reported in London, across both male and female Year 10 pupils during the 2023–2024 school year.
The UK Health Security Agency (UKHSA) and NHS England are now focusing on improving awareness and access for young adults who missed vaccination earlier in life.
HPV vaccine effectiveness and long-term plans
The NHS aims to eliminate cervical cancer by 2040 under its 10-Year Health Plan, which includes boosting vaccine uptake to 90% among girls and increasing participation in cervical screening.
The vaccine also helps prevent cancers of the mouth, throat, anus, penis and vagina caused by the human papillomavirus (HPV).
Introduced in 2021, the latest version of the HPV vaccine is more effective than the previous type. Long-term projections suggest it could reduce cases of women's cancer by 16% and HPV-related deaths by 9%.
Research in England shows that the vaccine prevents 90% of cervical cancer cases.
Catch-up vaccinations available for adults
Catch-up doses are available to:
Anyone up to age 25 who missed their school vaccination
Adults up to age 45 with immune-compromised conditions
Men who have sex with men
Dr Amanda Doyle, National Director for Primary Care and Community Services at NHS England, said: “Too many lives are lost to cervical cancer. The hard work of NHS staff in vaccinating and screening as many people as possible will help us meet our ambition of wiping out this disease.”
Dr Sharif Ismail, Director of Public Health Analysis at UKHSA, added: “Uptake of the HPV vaccination has dropped significantly since the pandemic, leaving thousands at greater risk. We urge all parents to return consent forms promptly, and young adults should speak to their GP about catch-up options. It’s never too late to get protected.”
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.
He now believes that commercial interests may be at odds with his philosophical mission
Bryan Johnson, 47, is contemplating shutting down or selling his anti-ageing startup, Blueprint.
The biotech entrepreneur recently launched a religion called "Don’t Die."
He says commercial activity is undermining his philosophical credibility.
Blueprint has faced financial pressures but Johnson denies any crisis.
Biotech entrepreneur and longevity enthusiast Bryan Johnson has revealed he is considering shutting down or selling his anti-ageing company, Blueprint. Speaking to Wired, the 47-year-old said his priorities have shifted towards developing his newly founded religion, "Don’t Die", which he believes better aligns with his philosophical ambitions.
“I am so close to either shutting it down or selling it,” Johnson said in the interview published Monday. “I don’t need the money, and it’s a pain-in-the-ass company.”
From business to belief
Johnson is widely known for Project Blueprint, his intense and expensive self-experimentation regimen aimed at reversing ageing. Launched in 2021, the programme reportedly costs him around $2 million annually and has included controversial practices such as blood transfusions from his son, which he later discontinued due to lack of observable benefits.
Blueprint, his startup, sells wellness products ranging from a £42 mushroom-based coffee alternative called “Super Shrooms” to a £44 “longevity mix” drink.
In March, Johnson publicly declared the founding of his own religion, “Don’t Die”, which evolved from the tagline of his wellness brand and Netflix documentary. “It seemed obvious that they’d say Don’t Die is how humanity saved itself and merged with AI,” he wrote on X.
However, he now believes that commercial interests may be at odds with his philosophical mission. “People see the business and give me less credibility on the philosophy side. I will not make that trade-off,” he told Wired.
Financial pressures and public perception
Earlier this year, The New York Times reported that Blueprint was missing its monthly break-even target by over £780,000 ($1 million), citing internal documents and former employees. Johnson responded to some of the allegations, but notably avoided directly addressing the financial data.
To Wired, he maintained that the company is not in a financial crisis. “We are break-even, and I’ve said that publicly many times. We’ve had profitable months, we’ve had loss months,” he said.
Blueprint originally emerged from requests by friends who were curious about the supplements Johnson was taking. “I was trying to do people a solid,” he said. Yet, the enterprise has grown into something that, he now feels, undermines the authenticity of his philosophical pursuits.
Morrisons Clinic introduces subscription service for tirzepatide injections
The treatment may aid weight loss of up to 20% over one year
Monthly subscription will increase from £129 to £159 after introductory period
Service includes medical assessment and regular check-ins
Criticism emerges over the supermarket’s continued sale of unhealthy food
Morrisons has launched an online subscription service offering weight loss injections, prompting mixed reactions from the public. The supermarket’s online health platform, Morrisons Clinic, now offers tirzepatide — also known by the brand name Mounjaro — for weight management.
Tirzepatide is primarily prescribed to treat type 2 diabetes, but has also been approved for weight loss. According to Morrisons Clinic, users may lose up to 20 per cent of their body weight over the course of a year.
Cost and treatment details
The service is priced at £129 for the first month, increasing to £159 thereafter. Before beginning treatment, customers are required to complete a medical assessment. Monthly check-ins with a clinical team are part of the subscription, and all prescriptions are handled by trained pharmacists.
“Our expert prescribing pharmacists are specially trained to review, consult and provide medications online,” the website states. “Your healthcare journey is in safe hands.”
The clinic describes its services as being “designed with your long-term health as our priority.”
Backlash over perceived mixed messaging
The move has sparked criticism on social media, with some users accusing the chain of hypocrisy. Critics pointed out that while the supermarket offers medical treatment for weight loss, it also continues to sell ultra-processed, high-fat and high-sugar foods.
One user commented: “It’s genius really. The store sells you unhealthy grub that gets you fat, then wants vast sums of money to get you thin.” Another added: “Is this a parody? One of the culprits, pushing highly processed food, is offering a fat clinic?!”
Morrisons defends online clinic
In response, Morrisons has defended the initiative, stating that its weight loss services are “prescribed and dispensed responsibly.” The clinic offers a range of other health services, including treatments for:
Premature ejaculation (£26.99)
Acne (£36.99)
Acid reflux (£17.99)
Erectile dysfunction (£13)
Migraines (£15.99)
Keep ReadingShow less
NHS England says premature babies are three times more likely to be hospitalised due to RSV
NHS to offer nirsevimab injection to 9,000 premature and high-risk babies from late September
Aims to protect against respiratory syncytial virus (RSV), which can cause severe illness in infants
Premature babies are 10 times more likely to need intensive care for RSV
Nirsevimab offers immediate protection and lasts for six months
Neo-natal units across the UK will deliver the jab
Thousands of premature and high-risk babies in the UK will soon be offered a new immunisation to protect against RSV (respiratory syncytial virus), a common winter virus that can cause serious lung infections and hospitalisation. The NHS will begin delivering the nirsevimab injection from late September, aiming to shield vulnerable infants before the colder months set in.
Premature infants at higher risk from RSV
RSV typically causes coughs and colds, but in some children — particularly those born prematurely or with underlying health conditions — it can lead to bronchiolitis, pneumonia, and breathing difficulties. NHS England says premature babies are three times more likely to be hospitalised due to RSV and ten times more likely to require intensive care compared to full-term infants.
Each year, around 30,000 children under five are admitted to hospital in the UK with RSV, and approximately 30 of them die from complications related to the virus.
New immunisation to deliver immediate protection
While most full-term babies receive protection through maternal vaccination during late pregnancy, those born before 32 weeks miss the opportunity to build sufficient immunity. These infants will now be offered nirsevimab, a long-acting antibody that provides immediate protection for six months in just one dose.
Unlike traditional vaccines that take time to activate the body’s immune response, nirsevimab delivers ready-made antibodies, offering instant defence against infection.
NHS clinics to deliver jabs across the UK
Neo-natal clinics throughout England, Scotland, Wales, and Northern Ireland will administer the injection. Families of vulnerable infants — including those with heart or lung conditions or weakened immune systems — will be advised on how to access the immunisation by their healthcare teams.
Dr Claire Fuller, co-national medical director for NHS England, said the immunisation “will offer a long-lasting defence, helping to avoid unnecessary hospitalisations and serious illness, giving babies the best possible start in life and shielding them from harm.”
Clinical trial success and personal testimony
Ceri Cox, a 33-year-old paediatric nurse, enrolled her two-year-old son Harry in an international clinical trial for nirsevimab at University Hospital Southampton. Having seen the effects of RSV firsthand, she described the rollout as “amazing” and hopes it will help reduce the number of young patients in hospital this winter.
Background on RSV and current vaccination efforts
In 2023, the UK introduced a maternal vaccination programme offering the RSV jab Abrysvo to pregnant women from 28 weeks and to adults aged 75 to 79. The vaccine boosts the mother’s immune system, passing protection to the baby during the first few weeks of life. However, this method is not viable for premature births, hence the need for nirsevimab.
RSV symptoms to watch for
RSV symptoms typically appear a few days after infection and include:
Runny or blocked nose
Cough
Sneezing
Fever or chills
Tiredness
Infants may also show:
Feeding difficulties
Irritability
Wheezing
Rapid or irregular breathing
Loss of appetite
Severe cases can escalate to pneumonia or bronchiolitis, particularly in high-risk infants.
Keep ReadingShow less
The diagnosis has prompted a wave of public attention
President Donald Trump has been diagnosed with chronic venous insufficiency (CVI), a vascular condition affecting blood flow in the legs
CVI occurs when leg veins struggle to return blood to the heart, often leading to swelling and discomfort
The condition was confirmed following visible leg swelling and bruising
Though not life-threatening, CVI can worsen without treatment
Trump’s case has sparked public interest in the risks and management of the condition
Trump diagnosed with common but chronic vein condition
President Donald Trump has been diagnosed with chronic venous insufficiency, a condition that affects the proper circulation of blood in the legs. The announcement followed public speculation after Trump was seen with visible swelling in his lower legs and bruising on his hand during recent public appearances.
According to a statement from White House medical staff, tests ruled out more serious cardiovascular conditions. Trump, 79, remains under regular observation, with the condition described as benign and manageable.
What is chronic venous insufficiency?
Chronic venous insufficiency (CVI) is a long-term circulatory disorder in which the veins in the legs fail to efficiently pump blood back to the heart. This is typically caused by weakened or damaged valves inside the veins, leading to blood pooling or flowing backwards—a condition known as venous reflux.
Unlike a sudden or acute event such as a blood clot, CVI develops slowly over time, often unnoticed in its early stages.
What are the symptoms?
Symptoms can range from mild to more serious, and commonly include:
Swelling in the legs or ankles
Aching, cramping, or heaviness in the lower limbs
Visible varicose veins
Skin thickening or discolouration, especially near the ankles
In more advanced cases, ulcers or open sores
The symptoms often worsen after long periods of standing or sitting, and may ease with movement or leg elevation.
Who is at risk?
CVI is more common among:
Individuals aged 50 and above
People with a history of deep vein thrombosis (DVT)
Those who are overweight or sedentary
Individuals with high blood pressure
Pregnant women and those with a family history of venous disease
Age is a major risk factor, particularly for individuals in their 70s and beyond. Trump’s diagnosis falls within this common demographic.
How is it diagnosed and treated?
Diagnosis typically involves a clinical examination, followed by imaging tests such as duplex ultrasound to assess blood flow and valve function in the leg veins.
Treatment aims to relieve symptoms, prevent complications, and improve quality of life. Options include:
Compression stockings to improve circulation
Lifestyle modifications such as exercise, leg elevation, and weight management
Medications to reduce inflammation or thin the blood if needed
Minimally invasive procedures, such as laser therapy or sclerotherapy, for more severe cases
Trump’s condition is reportedly being managed conservatively, with no indication of surgical intervention at this time.
Why does it matter?
Although not life-threatening, CVI can affect comfort and mobility, especially in older adults. In Trump’s case, the diagnosis has prompted a wave of public attention, highlighting the pressures of health scrutiny for leaders in high office.
The condition itself is common and treatable, but left unmanaged, it can lead to chronic swelling, discomfort, and skin complications. Trump’s medical team has confirmed that his overall health remains stable, with regular monitoring in place.